Compare · DYN vs NVO
DYN vs NVO
Side-by-side comparison of Dyne Therapeutics Inc. (DYN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DYN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 60.8x DYN ($2.86B).
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for DYN).
- NVO has more recent analyst coverage (25 ratings vs 23 for DYN).
- Company
- Dyne Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $2.86B
- $173.66B
- 1M return
- -21.05%
- -
- 1Y return
- -13.03%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 3
- 4
- Recent ratings
- 23
- 25
Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DYN
- SEC Form 4 filed by Dyne Therapeutics Inc.
- Dyne Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dyne Therapeutics downgraded by Analyst with a new price target
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- Chief Commercial Officer Friedl-Naderer Johanna sold $25,408 worth of shares (1,085 units at $23.42) as part of a pre-agreed trading plan, decreasing direct ownership by 0.70% to 152,897 units (SEC Form 4) to cover taxes
- Chief Medical Officer Kerr Douglas sold $115,546 worth of shares (5,035 units at $22.95) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 162,564 units (SEC Form 4) (for withholding tax)
- CEO & President Cox John sold $106,823 worth of shares (5,658 units at $18.88) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 357,507 units (SEC Form 4) (tax withholding)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank